drugset / Trial / NCT04060914
LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
RandomizedParallel-groupOpen-labelTreatment
Summary
The hypothesis in this study was that ticagrelor switched to 60 mg after 1 month of standard dose, with antiplatelet activity that is not inferior to the standard dose and better than 75 mg clopidogrel for patients with ACS after PCI.
Timeline
- Start
- 2019-08-30
- Primary completion
- 2020-12-30
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Ticagrelor | Small molecule | 60 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |
| Comparator | Aspirin | Small molecule | — | — |